Do elevated TPOAb and TgAb indicate thyroid autoimmunity, and are CD40, CTLA4, and SH2B3 variants linked to susceptibility?

Autoimmune thyroid diseases arise from a complex interplay of active humoral immunity and underlying genetic susceptibility.

Clinical and immunological evidence

• Antibody-mediated tissue damage: Elevated thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) antibodies are primary clinical biomarkers of active, thyroid-directed autoimmune pathogenesis. TPOAb directly drives follicular cell destruction via complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC). Meanwhile, TgAb forms macromolecular immune complexes that enhance CD4+ T-cell activation. Together, these processes cause lymphocytic infiltration and progressive tissue damage, substantially increasing the risk of progressing to overt hypothyroidism.

Genetic and mechanistic pathways

• Breakdown of immune tolerance: Specific genetic polymorphisms impair immune checkpoints and peripheral T-cell tolerance to drive susceptibility. The CD40 rs1883832 (-1C>T) C allele increases CD40 protein expression, boosting B-cell activation and costimulation. CTLA4 variants, such as rs231775 and rs3087243, compromise inhibitory checkpoint function, allowing autoreactive T cells to escape regulation. Furthermore, SH2B3 variants (such as rs3184504) dysregulate intracellular JAK-STAT cytokine signaling, promoting a hyper-responsive inflammatory state that contributes to thyroid autoimmunity.

Bottom line

• Elevated TPOAb and TgAb indicate ongoing, cytotoxic thyroid tissue destruction and a high risk of hypothyroid progression, which is strongly underpinned by CD40, CTLA4, and SH2B3 genetic variants that collectively disrupt peripheral T-cell tolerance and costimulatory checkpoints.